Soma Pharmacy Blognews

Archive for October 2nd, 2009

Study: Chantix Has Little or No Suicide Risk

Posted by: SomaNews on: 02 Oct, 2009

Study: Chantix Has Little or No Suicide Risk
The antismoking drug Chantix has been linked to suicide and suicidal thoughts, but a new study shows that if such a risk exists it is likely to be very small.

Living to 100 to Become Common?

Posted by: SomaNews on: 02 Oct, 2009

Living to 100 to Become Common?
If life expectancy keeps rising, most babies born since 2000 in wealthy countries will live to 100, researchers predict in The Lancet.

Heart Defects, Mom’s Weight May Be Linked

Posted by: SomaNews on: 02 Oct, 2009

Heart Defects, Mom’s Weight May Be Linked
Being overweight or obese before pregnancy may be associated with a greater chance of having a baby with congenital heart defects, CDC researchers report.

Low-Cost Drugs Prevent Heart Attack, Stroke

Posted by: SomaNews on: 02 Oct, 2009

Low-Cost Drugs Prevent Heart Attack, Stroke
Giving two low-cost prescription drugs to reduce cholesterol and blood pressure in people with diabetes or heart disease — along with encouraging them to take a daily aspirin — can slash their risk of hospitalization for heart attack or stroke by 60%, according to a new study.

28 Pregnant Women Dead from H1N1 Swine Flu in U.S.

Posted by: SomaNews on: 02 Oct, 2009

28 Pregnant Women Dead from H1N1 Swine Flu in U.S.
H1N1 swine flu has killed 28 pregnant women in the U.S., raising the level of concern among obstetricians and CDC investigators.

Gene Linked to Longer, Skinnier Life

Posted by: SomaNews on: 02 Oct, 2009

Gene Linked to Longer, Skinnier Life
Scientists have discovered a gene called S6K1 that may affect longevity and leanness.

Actavis Launch Atorvastatin In Spain

Posted by: SomaNews on: 02 Oct, 2009

Actavis Launch Atorvastatin In Spain
Indicated for the treatment of hypercholesterolemia

InVivo, CEVEC pharmaceuticals Sign License Agreement

Posted by: SomaNews on: 02 Oct, 2009

InVivo, CEVEC pharmaceuticals Sign License Agreement
For the use of human CAP-T Technology for production of recombinant proteins

Sanofi-Aventis, Merrimack Enter Into Global Collaboration, Licensing Agreement
Sanofi receives license to develop, manufacture and commercialise MM-121

Opaxio Produces High Rates Of Pathologic Complete Remission In Patients with Advanced Esophageal Cancer
Study paves way for potential registration trial as radiation sensitiser


Categories

soma
ambien
duty free tobacco
Rolex Replica

Archives